Skip to main content

Table 2 Clinical characteristics of systemic lupus erythematosus patients according to global disease activity (n = 73)

From: The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study

 

Inactive SLE (n = 50)

Active SLE (n = 23)

p value§

Age, median (IQR) years

46 (35–59)

39 (30–52)

0.20

Female sex (%)

44 (88)

21 (91)

0.68

Caucasian, no. (%)

38 (76)

18 (78)

0.83

Higher education*, no./total (%)

20/39 (51)

10/20 (50)

0.93

Active smoker, no. (%)

9 (18)

8 (35)

0.12

Body mass index, median (IQR)

24 (20–29)

22 (19–24)

0.35

Use of psychiatric medication£, no. (%)

9 (18)

5 (22)

0.75

Disease duration, median (IQR) years

7 (3–15)

6 (3–15)

0.42

History of lupus nephritis, no (%)

19 (38)

6 (26)

0.31

History of neurolupus, no (%)

6 (12)

2 (7)

0.67

SELENA-SLEDAI, median (IQR) score

2 (0–2)

6 (4–10)

< 0.001

PGA score, median (IQR) score

0 (0–0)

1 (1–2)

< 0.001

Immunomodulators past month, no. (%)

44 (88)

20 (87)

0.90

 Antimalarials, no. (%)

37 (74)

15 (65)

0.44

 Systemic corticosteroids, no. (%)

26 (52)

13 (57)

0.72

 Immunosuppressants, no. (%)

25 (50)

10 (43)

0.60

  1. IQR interquartile range, SLE systemic lupus erythematosus
  2. *Active disease is defined as a Systemic Lupus Erythematosus Disease Activity Index score with the Safety of Estrogens in Lupus Erythematosus National Assessment modification (SELENA-SLEDAI) ≥ 4 and a Physician’s Global Assessment score (PGA) ≥ 1
  3. £Defined as any antidepressants, antipsychotics, and anxiolytics/hypnotics
  4. §p value < 0.05 is considered significant